Financial Lp Hrt Acquires 3,959 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt bought 3,959 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was acquired at an average cost of $3.30 per share, for a total transaction of $13,064.70. Following the completion of the transaction, the insider owned 82,556 shares in the company, valued at $272,434.80. This represents a 5.04% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, June 30th, Financial Lp Hrt purchased 6,755 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average cost of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt purchased 25,836 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average price of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Price Performance

SHPH opened at $3.65 on Friday. Shuttle Pharmaceuticals Holdings, Inc. has a 12-month low of $2.90 and a 12-month high of $55.90. The stock has a market capitalization of $2.34 million, a PE ratio of -0.08 and a beta of 0.29. The firm’s fifty day moving average price is $5.69 and its 200 day moving average price is $10.59.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.60 earnings per share for the quarter.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals in the fourth quarter valued at $26,000. Boothbay Fund Management LLC acquired a new position in shares of Shuttle Pharmaceuticals during the fourth quarter valued at $37,000. Ikarian Capital LLC bought a new position in shares of Shuttle Pharmaceuticals during the fourth quarter worth about $124,000. Finally, Connective Capital Management LLC bought a new position in shares of Shuttle Pharmaceuticals during the third quarter worth about $357,000. 4.58% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on SHPH. Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday. Wall Street Zen raised shares of Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .